ATE455119T1 - Thiazolo-, oxazalo und imidazolo- chinazolinverbindungen, die dazu fähig sind, proteinkinasen zu hemmen - Google Patents

Thiazolo-, oxazalo und imidazolo- chinazolinverbindungen, die dazu fähig sind, proteinkinasen zu hemmen

Info

Publication number: ATE455119T1
Authority: AT; Austria
Prior art keywords: group; alkyl; groups; optionally substituted; disorders
Prior art date: 2003-07-08

Application number

AT04743278T

Other languages

English (en)

Inventor

Campbell Mcinnes

Mark Thomas

Shudong Wang

Neil Mcintyre

Nicholas Westwood

Peter Fischer

Original Assignee

Cyclacel Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-08

Filing date

2004-07-07

Publication date

2010-01-15

2004-07-07 Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd

2010-01-15 Application granted granted Critical

2010-01-15 Publication of ATE455119T1 publication Critical patent/ATE455119T1/de

Links

KJMFQJFNQYWQAV-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinazoline Chemical class C1=NC=NC2=C(NC=N3)C3=CC=C21 KJMFQJFNQYWQAV-UHFFFAOYSA-N 0.000 title 1
102000001253 Protein Kinase Human genes 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
108060006633 protein kinase Proteins 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 5
125000003342 alkenyl group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
125000005842 heteroatom Chemical group 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
125000004122 cyclic group Chemical group 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229920006395 saturated elastomer Polymers 0.000 abstract 1
208000023516 stroke disease Diseases 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hematology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)

AT04743278T 2003-07-08 2004-07-07 Thiazolo-, oxazalo und imidazolo- chinazolinverbindungen, die dazu fähig sind, proteinkinasen zu hemmen ATE455119T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0315966.2A GB0315966D0 (en)	2003-07-08	2003-07-08	Compounds
PCT/GB2004/002935 WO2005005438A1 (en)	2003-07-08	2004-07-07	Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting prot ein kinases

Publications (1)

Publication Number	Publication Date
ATE455119T1 true ATE455119T1 (de)	2010-01-15

Family

ID=27741793

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04743278T ATE455119T1 (de)	2003-07-08	2004-07-07	Thiazolo-, oxazalo und imidazolo- chinazolinverbindungen, die dazu fähig sind, proteinkinasen zu hemmen

Country Status (12)

Country	Link
US (1)	US7576091B2 (de)
EP (1)	EP1641805B1 (de)
JP (1)	JP4653741B2 (de)
CN (1)	CN100404540C (de)
AT (1)	ATE455119T1 (de)
AU (1)	AU2004255924B8 (de)
BR (1)	BRPI0412363A (de)
CA (1)	CA2530455A1 (de)
DE (1)	DE602004025112D1 (de)
GB (1)	GB0315966D0 (de)
IL (1)	IL172993A0 (de)
WO (1)	WO2005005438A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0012528D0 (en) *	2000-05-23	2000-07-12	Univ Palackeho	Triterpenoid derivatives
GB0219052D0 (en) *	2002-08-15	2002-09-25	Cyclacel Ltd	New puring derivatives
GB0226583D0 (en) *	2002-11-14	2002-12-18	Cyclacel Ltd	Compounds
GB0229581D0 (en) *	2002-12-19	2003-01-22	Cyclacel Ltd	Use
CN1897950A (zh) *	2003-10-14	2007-01-17	惠氏公司	稠合芳基和杂芳基衍生物及其使用方法
WO2005061519A1 (en)	2003-12-19	2005-07-07	Takeda San Diego, Inc.	Kinase inhibitors
US7550598B2 (en)	2004-08-18	2009-06-23	Takeda Pharmaceutical Company Limited	Kinase inhibitors
RU2403258C2 (ru)	2004-10-07	2010-11-10	Бёрингер Ингельхайм Интернациональ Гмбх	Тиазолилдигидроиндазолы
DE602005023333D1 (de)	2004-10-15	2010-10-14	Takeda Pharmaceutical	Kinaseinhibitoren
JP2009506069A (ja)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	ムスカリン性受容体調節による神経発生
EP2258359A3 (de)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
DE102005048072A1 (de) *	2005-09-24	2007-04-05	Bayer Cropscience Ag	Thiazole als Fungizide
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US7985756B2 (en)	2005-10-21	2011-07-26	Braincells Inc.	Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
DE102006001161A1 (de) *	2006-01-06	2007-07-12	Qiagen Gmbh	Verfahren zum Nachweis von Cytosin-Methylierungen
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US20070238746A1 (en) *	2006-04-06	2007-10-11	Trixi Brandl	Thiazolyl-dihydro-chinazoline
US7517995B2 (en) *	2006-04-06	2009-04-14	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-cyclopentapyrazole
US7691868B2 (en)	2006-04-06	2010-04-06	Boehringer Ingelheim International Gmbh	Thiazolyl-dihydro-quinazoline
TW200808805A (en) *	2006-04-12	2008-02-16	Vertex Pharma	Tetrahydropteridines useful as inhibitors of protein kinases
WO2007134136A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
US8779154B2 (en) *	2006-09-26	2014-07-15	Qinglin Che	Fused ring compounds for inflammation and immune-related uses
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
WO2009047359A1 (en)	2007-10-12	2009-04-16	Ingenium Pharmaceuticals Gmbh	Inhibitors of protein kinases
EP2100894A1 (de)	2008-03-12	2009-09-16	4Sc Ag	Pyridopyrimidinone verwendbar als Plk1 (polo-like kinase) Hemmen
MX2010010975A (es) *	2008-04-07	2010-11-01	Amgen Inc	Amino piridinas/pirimidinas gem-disustituidas y espirociclicas como inhibidores de ciclo celular.
WO2010043676A1 (en) *	2008-10-17	2010-04-22	Boehringer Ingelheim International Gmbh	Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
ES2432671T3 (es)	2009-07-02	2013-12-04	Novartis Ag	2-carboxamida cicloamino ureas útiles como inhibidores de PI3K
US8518948B2 (en)	2010-03-10	2013-08-27	Ingenium Pharmaceuticals Gmbh	Inhibitors of protein kinases
WO2013059634A1 (en)	2011-10-20	2013-04-25	The Regents Of The University Of California	Use of cdk9 inhibitors to reduce cartilage degradation
US10300073B2 (en)	2014-10-14	2019-05-28	The Regents Of The University Of California	Use of CDK9 and BRD4 inhibitors to inhibit inflammation
US20170283445A1 (en)	2016-04-05	2017-10-05	University Of South Carolina	Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
CN114213421A (zh) *	2017-04-01	2022-03-22	晟科药业（江苏）有限公司	1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
JP7233743B2 (ja) *	2017-08-11	2023-03-07	晟科薬業（江蘇）有限公司	プロテインキナーゼ阻害剤としての１ｈ－ピラゾロ［４，３－ｈ］キナゾリン系化合物
US11162083B2 (en)	2018-06-14	2021-11-02	University Of South Carolina	Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en)	2019-02-15	2022-07-12	Incyte Corporation	Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh)	2019-03-05	2021-01-01	美商英塞特公司	作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en)	2019-03-29	2020-10-08	Incyte Corporation	Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en)	2019-05-01	2022-09-13	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
EP3992196B1 (de) *	2019-08-02	2023-12-13	Chengdu Cynogen Bio-Pharmaceutical Technology Co., Ltd.	1h-[1, 2, 3]triazolo[4, 5-h] chinazolin-verbindungen als proteinkinaseinhibitoren
CN116348458A (zh)	2019-08-14	2023-06-27	因赛特公司	作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN119930611A (zh)	2019-10-11	2025-05-06	因赛特公司	作为cdk2抑制剂的双环胺
EP4204093A1 (de) *	2020-08-27	2023-07-05	Shengke Pharmaceuticals (Jiangsu) Ltd.	1h-imidazo[4,5-h! chinazolin-verbindung als neue selektive flt3-inhibitoren
US12559733B2 (en)	2020-10-22	2026-02-24	University Of South Carolina	Optimization of type IV BRAF inhibitors for the treatment of melanoma
WO2022111634A1 (zh) *	2020-11-26	2022-06-02	成都赛璟生物医药科技有限公司	杂芳基并喹唑啉类化合物作为蛋白激酶抑制剂
EP4284371A4 (de) *	2021-01-29	2024-12-18	Virokyne Therapeutics, Llc	Selektive cyclinabhängige kinasehemmer und verfahren zur therapeutischen verwendung davon
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
CN121368595A (zh) *	2023-06-01	2026-01-20	成都赛璟生物医药科技有限公司	1h-[1,2,3]三唑并[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2026024674A1 (en)	2024-07-22	2026-01-29	Genesis Therapeutics, Inc.	Methods of treating skp2-associated cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5654307A (en) *	1994-01-25	1997-08-05	Warner-Lambert Company	Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
AU2001242629B2 (en) *	2000-03-29	2005-08-11	Cyclacel Limited	2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
EP1345925B1 (de) *	2000-12-21	2006-05-17	Vertex Pharmaceuticals Incorporated	Pyrazolverbindungen als proteinkinasehemmer

2003
- 2003-07-08 GB GBGB0315966.2A patent/GB0315966D0/en not_active Ceased
2004
- 2004-07-07 AT AT04743278T patent/ATE455119T1/de not_active IP Right Cessation
- 2004-07-07 DE DE602004025112T patent/DE602004025112D1/de not_active Expired - Fee Related
- 2004-07-07 EP EP04743278A patent/EP1641805B1/de not_active Expired - Lifetime
- 2004-07-07 BR BRPI0412363-8A patent/BRPI0412363A/pt not_active IP Right Cessation
- 2004-07-07 AU AU2004255924A patent/AU2004255924B8/en not_active Expired - Fee Related
- 2004-07-07 JP JP2006518353A patent/JP4653741B2/ja not_active Expired - Fee Related
- 2004-07-07 CN CNB2004800257284A patent/CN100404540C/zh not_active Expired - Fee Related
- 2004-07-07 CA CA002530455A patent/CA2530455A1/en not_active Abandoned
- 2004-07-07 WO PCT/GB2004/002935 patent/WO2005005438A1/en not_active Ceased
2006
- 2006-01-05 IL IL172993A patent/IL172993A0/en unknown
- 2006-01-06 US US11/326,805 patent/US7576091B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US7576091B2 (en)	2009-08-18
CN1849325A (zh)	2006-10-18
AU2004255924B8 (en)	2009-07-09
CA2530455A1 (en)	2005-01-20
EP1641805A1 (de)	2006-04-05
BRPI0412363A (pt)	2006-09-05
IL172993A0 (en)	2006-06-11
CN100404540C (zh)	2008-07-23
WO2005005438A1 (en)	2005-01-20
DE602004025112D1 (de)	2010-03-04
AU2004255924B2 (en)	2009-07-02
JP4653741B2 (ja)	2011-03-16
JP2007516202A (ja)	2007-06-21
GB0315966D0 (en)	2003-08-13
AU2004255924A1 (en)	2005-01-20
EP1641805B1 (de)	2010-01-13
US20060264628A1 (en)	2006-11-23

Legal Events

Date	Code	Title	Description
2010-07-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE602004025112D1 (de)	2010-03-04	Thiazolo-, oxazalo und imidazolo-chinazolinverbindungen, die dazu fähig sind, proteinkinasen zu hemmen
RU2003132687A (ru)	2005-04-10	Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv
SE0202133D0 (sv)	2002-07-08	Novel compounds
PE20121354A1 (es)	2012-10-15	Inhibidores del virus de la hepatitis c
AR078542A1 (es)	2011-11-16	Moduladores de gpr40 de pirrolidina
EA200601785A1 (ru)	2007-02-27	Соединения и способы лечения дислипидемии
EA200500342A1 (ru)	2005-08-25	Гетероциклические замещённые пиперазины для лечения шизофрении
PE20141075A1 (es)	2014-09-06	4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina
NZ528851A (en)	2006-03-31	N-aroyl cyclic amines
BR0215202A (pt)	2004-10-13	Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
FR2842804B1 (fr)	2004-09-03	Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EA200870358A1 (ru)	2009-02-27	2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
AR048376A1 (es)	2006-04-26	C- glicosidos heterociclos fusionados sustituidos
BRPI0510598A (pt)	2007-11-20	compostos de amida de aril ou heteroaril substituìdos
NO20050741L (no)	2005-08-15	Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den
PE20050420A1 (es)	2005-06-13	Fenacilo 2-hidroxi-3-diaminoalcanos
DE602004031722D1 (de)	2011-04-21	Kondensierte bizyklisch substituierte amine als histamin 3 rezeptor liganden
RU2009146124A (ru)	2011-06-20	Дигидрохиноновые и дигидронафтиридиновые ингибиторы киназы jnk
DE60322877D1 (de)	2008-09-25	Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität
SE0303541D0 (sv)	2003-12-22	New compounds
PE20030718A1 (es)	2003-08-18	Lactamas como antagonistas de taquiquininas
ATE503746T1 (de)	2011-04-15	Neue imidazolidinderivate
PE20040531A1 (es)	2004-09-27	Derivados de isoindolona, proceso de preparacion, compuestos intermedios de este proceso y composiciones farmaceuticas que los contienen
JP2020502116A5 (de)	2021-02-04
DE602004029355D1 (de)	2010-11-11	Sulfopyrrolderivate